Vojenská Nemocnice Brno

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Crohn's disease3 trials
• Obesity3 trials
• Ulcerative colitis3 trials
• Heart failure2 trials
• Chronic kidney disease1 trial
• Coronary artery disease1 trial
• Peripheral artery disease1 trial
• Stroke1 trial
• Type 2 diabetes1 trial

Phase

• Phase 38 trials
• Phase 41 trial

Status

• Active, not recruiting4 trials
• Completed2 trials
• Recruiting2 trials
• Not yet recruiting1 trial

Lead sponsor

• Eli Lilly and Company5 trials
• Amgen2 trials
• Alimentiv Inc.1 trial
• Janssen Research & Development, LLC1 trial

Running trials

• Recruiting

  A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT07499232· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Recruiting

  VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

  NCT06257706· Phase 4· Alimentiv Inc.· Source

  Contact: David Stepek, MD (principal investigator)

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

  NCT04232553· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

  NCT03519945· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease2 recruiting
• Heart failure1 recruiting
• Obesity1 recruiting

Closed trials

• Completed

  A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092· Phase 3· Eli Lilly and Company· Source

• Completed

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Phase 3· Eli Lilly and Company· Source